Randy Dockens

1.6k total citations
36 papers, 751 citations indexed

About

Randy Dockens is a scholar working on Oncology, Pharmacology and Pharmacology. According to data from OpenAlex, Randy Dockens has authored 36 papers receiving a total of 751 indexed citations (citations by other indexed papers that have themselves been cited), including 10 papers in Oncology, 8 papers in Pharmacology and 7 papers in Pharmacology. Recurrent topics in Randy Dockens's work include Pharmacogenetics and Drug Metabolism (7 papers), Cholinesterase and Neurodegenerative Diseases (5 papers) and Drug Transport and Resistance Mechanisms (4 papers). Randy Dockens is often cited by papers focused on Pharmacogenetics and Drug Metabolism (7 papers), Cholinesterase and Neurodegenerative Diseases (5 papers) and Drug Transport and Resistance Mechanisms (4 papers). Randy Dockens collaborates with scholars based in United States, Germany and Sweden. Randy Dockens's co-authors include Daniel E. Salazar, Gary Tong, Robert Croop, Rashmi H. Barbhaiya, Douglas S. Greene, Huidong Gu, Charles R. Clark, William R. Ravis, Junsheng Wang and Patricia D. Kroboth and has published in prestigious journals such as Gastroenterology, Analytical Chemistry and Journal of Medicinal Chemistry.

In The Last Decade

Randy Dockens

36 papers receiving 736 citations

Peers

Countries citing papers authored by Randy Dockens

Since Specialization

Citations

This map shows the geographic impact of Randy Dockens's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Randy Dockens with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Randy Dockens more than expected).

Fields of papers citing papers by Randy Dockens

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Randy Dockens. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Randy Dockens. The network helps show where Randy Dockens may publish in the future.

Co-authorship network of co-authors of Randy Dockens

This figure shows the co-authorship network connecting the top 25 collaborators of Randy Dockens. A scholar is included among the top collaborators of Randy Dockens based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Randy Dockens. Randy Dockens is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Pharmacokinetics and Safety of the Tyrosine Kinase 2 Inhibitor Deucravacitinib in Healthy Chinese Subjects 2023 ·Dermatology and Therapy ·(unknown), (unknown), Randy Dockens, (unknown), Bing He, Ihab Girgis, Anjaneya Chimalakonda, Bindu Murthy, (unknown)	3
2	Pre-absorption physicochemical compatibility assessment of 8-drug metabolic cocktail 2016 ·International Journal of Pharmaceutics ·Ching Kim Tye, Zhanbin Wang, Randy Dockens, Blisse Vakkalagadda, Chunlei Wang, Yingru Zhang, Ching Su, Michael J. Hageman	4
3	Multicenter, Randomized, Double-Blind, Placebo-Controlled, Single-Ascending Dose Study of the Oral γ-Secretase Inhibitor BMS-708163 (Avagacestat): Tolerability Profile, Pharmacokinetic Parameters, and Pharmacodynamic Markers 2012 ·Clinical Therapeutics ·Gary Tong, Junsheng Wang, Oleksandr Sverdlov, Shu‐Pang Huang, Randy Slemmon, Robert Croop, (unknown), Huidong Gu, Oi T. Wong, Hewei Li, Robert Berman, (unknown), Charles F. Albright, Randy Dockens	54
4	Effects of Single Doses of Avagacestat (BMS-708163) on Cerebrospinal Fluid Aβ Levels in Healthy Young Men 2012 ·Clinical Drug Investigation ·Gary Tong, (unknown), Junsheng Wang, Oleksandr Sverdlov, Shu‐Pang Huang, Randy Slemmon, Huidong Gu, Oi T. Wong, Hewei Li, Robert Berman, (unknown), Charles F. Albright, Randy Dockens	26
5	A Placebo-Controlled, Multiple Ascending Dose Study to Evaluate the Safety, Pharmacokinetics and Pharmacodynamics of Avagacestat (BMS-708163) in Healthy Young and Elderly Subjects 2012 ·Clinical Pharmacokinetics ·Randy Dockens, Junsheng Wang, (unknown), Oleksandr Sverdlov, Shu‐Pang Huang, Randy Slemmon, Huidong Gu, Oi T. Wong, Hewei Li, Robert Berman, (unknown), Charles F. Albright, Gary Tong	36
6	A contrast in safety, pharmacokinetics and pharmacodynamics across age groups after a single 50 mg oral dose of the γ‐secretase inhibitor avagacestat 2012 ·British Journal of Clinical Pharmacology ·Gary Tong, Junsheng Wang, Oleksandr Sverdlov, Shu‐Pang Huang, Randy Slemmon, Robert Croop, (unknown), Huidong Gu, Oi T. Wong, Hewei Li, Robert Berman, (unknown), Charles F. Albright, Randy Dockens	12
7	Calculation and Mitigation of Isotopic Interferences in Liquid Chromatography–Mass Spectrometry/Mass Spectrometry Assays and Its Application in Supporting Microdose Absolute Bioavailability Studies 2012 ·Analytical Chemistry ·Huidong Gu, Jian Wang, Anne‐Françoise Aubry, Hao Jiang, Jianing Zeng, (unknown), Junsheng Wang, Randy Dockens, Marc Bifano, Richard C. Burrell, Mark E. Arnold	32
8	P3‐298: The safety, tolerability, pharmacokinetics and pharmacodynamics of single doses of BMS‐708163 in young and elderly subjects 2010 ·Alzheimer s & Dementia ·Gary Tong, (unknown), (unknown), Shu‐Pang Huang, Randy Slemmon, Robert Croop, (unknown), Huidong Gu, Oi T. Wong, Hewei Li, Robert Berman, (unknown), Charles F. Albright, Randy Dockens, Santiago Arroyo	2
9	Multicenter, randomized, double-blind, active comparator and placebo-controlled trial of a corticotropin-releasing factor receptor-1 antagonist in generalized anxiety disorder 2010 ·Depression and Anxiety ·Vladimir Coric, Howard Feldman, Dan A. Oren, Anantha Shekhar, Joseph Pultz, Randy Dockens, Xiaoling Wu, (unknown), Shu-Pang Huang, (unknown), Terrye Delmonte, (unknown), Daniel L. Zimbroff, Jack A. Grebb, Andrew W. Goddard, Elyse Stock	136
10	Do corticotropin releasing factor-1 receptors influence colonic transit and bowel function in women with irritable bowel syndrome? 2009 ·American Journal of Physiology-Gastrointestinal and Liver Physiology ·Seth Sweetser, Michael Camilleri, (unknown), Duane D. Burton, (unknown), Robert Croop, Gary Tong, Randy Dockens, Alan R. Zinsmeister	92
11	T1405 Effects of a Novel Corticotrophin Releasing Factor Receptor-1 Antagonist, BMS-562086, On Gastrointestinal and Colonic Transit and Bowel Habits in Patients with Diarrhea-Predominant Irritable Bowel Syndrome (D-IBS) 2008 ·Gastroenterology ·Seth Sweetser, (unknown), Duane D. Burton, April Grudell, Deborah J. Eckert, (unknown), Irene Busciglio, Gary Tong, Randy Dockens, Alan R. Zinsmeister, Michael Camilleri	7
12	Disposition and Metabolism of [14C]Brasofensine in Rats, Monkeys, and Humans 2007 ·Drug Metabolism and Disposition ·(unknown), Daisy B. Whigan, Shu Chang, Randy Dockens	5
13	Pharmacokinetics of 6‐hydroxybuspirone and its enantiomers administered individually or following buspirone administration in humans 2007 ·Biopharmaceutics & Drug Disposition ·Randy Dockens, (unknown), Jianing Zeng, Robert Croop	5
14	6-Hydroxybuspirone Is a Major Active Metabolite of Buspirone: Assessment of Pharmacokinetics and 5-Hydroxytryptamine1A Receptor Occupancy in Rats 2007 ·Drug Metabolism and Disposition ·Harvey Wong, Randy Dockens, (unknown), Suresh Yeola, James E. Grace, Arlene Stark, Rebecca Taub, Frank D. Yocca, Robert Zaczek, Yuwen Li	27
15	Pharmacokinetics of a Newly Identified Active Metabolite of Buspirone After Administration of Buspirone Over Its Therapeutic Dose Range 2006 ·The Journal of Clinical Pharmacology ·Randy Dockens, Daniel E. Salazar, (unknown), (unknown), Mark E. Arnold, Robert Croop	19
16	Pharmacokinetics and Tolerability of Buspirone during Oral Administration to Children and Adolescents with Anxiety Disorder and Normal Healthy Adults 2001 ·The Journal of Clinical Pharmacology ·Daniel E. Salazar, Edyta J. Frackiewicz, Randy Dockens, Georgia Kollia, (unknown), (unknown), Howard D. Uderman, Thomas Shiovitz, John J. Sramek, Neal R. Cutler	27
17	THE LACK EFFECT OF FOOD ON THE BIOAVAILABILITY OF NEFAZODONE TABLETS 1996 ·Biopharmaceutics & Drug Disposition ·Randy Dockens, Douglas S. Greene, Rashmi H. Barbhaiya	6
18	Coadministration of Nefazodone and Benzodiazepines 1995 ·Journal of Clinical Psychopharmacology ·Douglas S. Greene, Daniel E. Salazar, Randy Dockens, Patricia D. Kroboth, Rashmi H. Barbhaiya	11
19	Pharmacokinetic and Pharmacodynamic Evaluation of Warfarin and Nefazodone Coadministration in Healthy Subjects 1995 ·The Journal of Clinical Pharmacology ·Daniel E. Salazar, Randy Dockens, (unknown), Ralph Raymond, (unknown), Philip Chaikin, Howard D. Uderman	24
20	Coadministration of Nefazodone and Benzodiazepines 1995 ·Journal of Clinical Psychopharmacology ·Douglas S. Greene, Daniel E. Salazar, Randy Dockens, Patricia D. Kroboth, Rashmi H. Barbhaiya	47

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact